PMID- 32863913
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 20
IP  - 4
DP  - 2020 Oct
TI  - miR-375-3p inhibits the progression of laryngeal squamous cell carcinoma by 
      targeting hepatocyte nuclear factor-1beta.
PG  - 80
LID - 10.3892/ol.2020.11941 [doi]
LID - 80
AB  - Laryngeal squamous cell carcinoma (LSCC) is one of the most frequently diagnosed 
      head and neck cancers worldwide. Increasing evidence suggests that microRNAs 
      (miRNAs/miRs) regulate the progression of tumorigenesis and the malignant 
      behaviors of cancer cells. The aim of this study was to investigate the function 
      and underlying mechanism of miR-375-3p in LSCC. The expression of miR-375-3p in 
      LSCC tissues and cells was detected using reverse transcription-quantitative PCR. 
      The effects of miR-375-3p on the malignant phenotype of LSCC cells was determined 
      using the Cell Counting Kit-8 assay and flow cytometry. The targets of miR-375-3p 
      were predicted using the miRDB database and confirmed by the luciferase reporter 
      assay. The results of the present study demonstrated that miR-375-3p was 
      downregulated in LSCC tissues and cell lines. Furthermore, overexpression of 
      miR-375-3p significantly suppressed the proliferation and cell cycle progression 
      of LSCC cells. Overexpression of miR-375-3p also increased LSCC cell apoptosis. 
      Mechanistical analysis indicated that miR-375-3p bound the 3'-untranslated region 
      of the hepatocyte nuclear factor 1beta (HNF1beta) and decreased its expression in LSCC 
      cells. Consistent with the role of HNF1beta in glucose metabolism, overexpression of 
      miR-375-3p significantly inhibited glucose consumption and lactate production in 
      LSCC cells. Transfection with HNF1beta notably reversed the inhibitory effect of 
      miR-375-3p on the proliferation of LSCC cells. Collectively, these results 
      indicate the tumor suppressive role of miR-375-3p in LSCC via HNF1beta, suggesting 
      that miR-375-3p may serve as a potential target in the treatment of LSCC.
CI  - Copyright: (c) Chang et al.
FAU - Chang, Kunpeng
AU  - Chang K
AD  - Department of Otolaryngology Head and Neck Surgery, Luoyang Central Hospital 
      Affiliated to Zhengzhou University, Luoyang, Henan 471000, P.R. China.
FAU - Wei, Zhenxing
AU  - Wei Z
AD  - Department of Otolaryngology Head and Neck Surgery, Luoyang Central Hospital 
      Affiliated to Zhengzhou University, Luoyang, Henan 471000, P.R. China.
FAU - Cao, Hua
AU  - Cao H
AD  - Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200803
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC7436894
OTO - NOTNLM
OT  - hepatocyte nuclear factor-1beta
OT  - laryngeal squamous cell carcinoma
OT  - microRNA-375-3p
EDAT- 2020/08/31 06:00
MHDA- 2020/08/31 06:01
PMCR- 2020/08/03
CRDT- 2020/09/01 06:00
PHST- 2019/03/24 00:00 [received]
PHST- 2020/05/21 00:00 [accepted]
PHST- 2020/09/01 06:00 [entrez]
PHST- 2020/08/31 06:00 [pubmed]
PHST- 2020/08/31 06:01 [medline]
PHST- 2020/08/03 00:00 [pmc-release]
AID - OL-0-0-11941 [pii]
AID - 10.3892/ol.2020.11941 [doi]
PST - ppublish
SO  - Oncol Lett. 2020 Oct;20(4):80. doi: 10.3892/ol.2020.11941. Epub 2020 Aug 3.